Emerging evidence have suggested GAS5 as an indicator of overall survival in hepatocellular carcinoma, cervical cancer, gastric cancer, breast cancer, and colorectal cancer [15, 16, 21, 29, 31]. Here, GAS5 is linked to breast carcinoma.